Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL

Jul 5

Written By Team Rxtrospect

Team Rxtrospect

FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor

RxTROSPECT, Inc 2025 — All rights reserved. “RxTROSPECT” refers to RxTROSPECT, Inc.. RxTROSPECT, Inc. is an intelligence company offering a range of data and analytics products through its partnerships with Tableau, LLC (a subsidiary of Salesforce, Inc), and Mango Technologies, Inc. dba ClickUp.

Testimonials are specific to an individual Customer’s experience and may not be representative of all Customers. Unless otherwise indicated, Customers offering a Testimonial do not receive compensation and their statement does not present a conflict of interest.

RxTROSPECT is not affiliated with, sponsored, or endorsed by the companies listed, described, or featured on its site. Company logos or trademarks used do not imply endorsement and are the property of their respective owners.

This is a representative list of customers that work with RxTROSPECT as of January 1st, 2025. It is not known whether they approve or disapprove of our products.

Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL

FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

solutions

ABOUT US

RESOURCES